[Form 4] Helix Acquisition Corp. II Insider Trading Activity
BridgeBio Oncology Therapeutics, Inc. director Jake Bauer reported acquisition of a stock option on 08/26/2025. The Form 4 discloses a grant (transaction code A) of a Stock Option (Right to Buy) covering 138,193 underlying shares of Common Stock with an exercise price of $9.59. The form shows 138,193 derivative securities beneficially owned following the transaction and lists the option as direct ownership. The table includes a date field of 08/25/2035 in the exercisable/expiration column. The filing includes a vesting description: vesting is tied to an S-8 filing and then monthly vesting over a 48-month schedule measured from an April 25, 2025 vesting commencement date. The Form 4 was signed by an attorney-in-fact on 08/28/2025.
BridgeBio Oncology Therapeutics, Inc. il direttore Jake Bauer ha dichiarato l'acquisizione di un'opzione su azioni in data 26/08/2025. Il Modulo 4 segnala una concessione (codice transazione A) di una Stock Option (Diritto di Acquisto) relativa a 138.193 azioni ordinarie sottostanti, con prezzo di esercizio pari a $9,59. Il documento riporta la detenzione di 138.193 titoli derivati dopo l'operazione e indica che l'opzione 猫 di propriet脿 diretta. Nella tabella la colonna esercitabile/scadenza riporta la data 25/08/2035. La nota sul vesting specifica che la maturazione 猫 subordinata al deposito di un S-8 e poi avviene mensilmente su un periodo di 48 mesi a partire dalla data di inizio del vesting del 25 aprile 2025. Il Modulo 4 猫 stato firmato da un procuratore il 28/08/2025.
BridgeBio Oncology Therapeutics, Inc. el director Jake Bauer inform贸 la adquisici贸n de una opci贸n sobre acciones el 26/08/2025. El Formulario 4 revela una concesi贸n (c贸digo de transacci贸n A) de una Stock Option (Derecho de Compra) sobre 138.193 acciones ordinarias subyacentes, con un precio de ejercicio de $9,59. El formulario indica la tenencia de 138.193 valores derivados tras la operaci贸n y clasifica la opci贸n como propiedad directa. La tabla muestra la fecha 25/08/2035 en la columna de ejercitable/vencimiento. La presentaci贸n incluye una descripci贸n del vesting: la adquisici贸n de derechos est谩 sujeta a la presentaci贸n del formulario S-8 y, a continuaci贸n, se produce un vesting mensual durante 48 meses contado desde la fecha de inicio de vesting del 25 de abril de 2025. El Formulario 4 fue firmado por un apoderado el 28/08/2025.
BridgeBio Oncology Therapeutics, Inc.鞚� 鞚挫偓 Jake Bauer電� 2025-08-26鞐� 鞀ろ啞鞓奠厴鞚� 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. Form 4電� 瓯半灅旖旊摐 A搿� 響滉赴霅� 鞀ろ哑鞓奠厴(毵れ垬甓�) 攵�鞐ゼ 瓿店皽頃橂┌, 旮办磮 氤错喌欤� 138,193欤检棎 雽�頃� 甓岆Μ鞚搓碃 頄夓偓臧�瓴╈潃 $9.59鞛呺媹雼�. 頃措嫻 靹滊鞐愲姅 瓯半灅 頉� 韺岇儩歃濌秾 138,193欤茧ゼ 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 旮办灛霅橃柎 鞛堨溂氅�, 鞓奠厴鞚� 歆侅为 靻岇湢搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 響滌潣 頄夓偓/毵岆 旃胳棎電� 2035-08-25霛茧姅 雮犾臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氩犾姢韺� 靹る獏鞐愲姅 氩犾姢韺� 臧滌嫓臧� S-8 鞝滌稖鞐� 鞐半彊霅橂┌, 攴� 頉� 2025雲� 4鞗� 25鞚�鞚� 氩犾姢韺� 臧滌嫓鞚茧攵�韯� 48臧滌洈鞐� 瓯胳硱 毵れ洈 氩犾姢韺呺悳雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Form 4電� 雽�毽澑鞚� 2025-08-28鞐� 靹滊獏頄堨姷雼堧嫟.
BridgeBio Oncology Therapeutics, Inc. : le directeur Jake Bauer a d茅clar茅 l'acquisition d'une option d'achat d'actions le 26/08/2025. Le formulaire 4 d茅voile une attribution (code de transaction A) d'une Stock Option (droit d'achat) couvrant 138鈥�193 actions ordinaires sous-jacentes, avec un prix d'exercice de 9,59 $. Le formulaire indique la d茅tention de 138鈥�193 titres d茅riv茅s apr猫s la transaction et pr茅cise que l'option est en propri茅t茅 directe. Le tableau affiche la date 25/08/2035 dans la colonne exer莽able/expiration. La description du vesting pr茅cise que la mont茅e de droits d茅pend du d茅p么t d'un S-8, puis se r茅alise mensuellement sur 48 mois 脿 compter de la date de commencement du vesting du 25 avril 2025. Le formulaire 4 a 茅t茅 sign茅 par un mandataire le 28/08/2025.
BridgeBio Oncology Therapeutics, Inc.-Direktor Jake Bauer meldete den Erwerb einer Aktienoption am 26.08.2025. Das Formular 4 gibt einen Zuschuss (Transaktionscode A) einer Stock Option (Kaufrecht) 眉产别谤 138.193 zugrunde liegende Stammaktien mit einem Aus眉bungspreis von $9,59 an. Das Formular weist 138.193 derivativen Wertpapiere nach der Transaktion aus und nennt die Option als direktes Eigentum. In der Tabelle steht in der Spalte Aus眉bbar/Verfall das Datum 25.08.2035. Zur Vesting-Regelung hei脽t es, dass das Vesting an die Einreichung eines S-8 gebunden ist und anschlie脽end 眉产别谤 einen Zeitraum von 48 Monaten monatlich erfolgt, gemessen ab dem Vesting-Beginn am 25. April 2025. Das Formular 4 wurde am 28.08.2025 von einem Bevollm盲chtigten unterschrieben.
- Director alignment through equity: a sizeable option grant (138,193 shares) aligns the reporting person's interests with shareholders
- Clear vesting schedule: vesting terms are explicitly described and tied to an S-8 filing with monthly vesting over 48 months
- Limited exercisability/expiration clarity: the form lists 08/25/2035 in the exercisable/expiration column but does not clarify full exercisability timing
- No dollar-value disclosure: the filing does not include grant fair-value or other economic terms beyond exercise price
Insights
TL;DR: Routine director equity grant: large option award aligns incentive but contains standard multi-year vesting tied to an S-8 registration.
The filing documents a single derivative acquisition by a director under transaction code A, indicating an option grant for 138,193 shares at $9.59 per share. The option is recorded as directly beneficially owned after the grant. The vesting mechanics are explicit: an initial fractional vesting upon effectiveness of an S-8 registration based on months elapsed since April 25, 2025, then monthly vesting over a 48-month schedule until fully vested. The exercisable/expiration date field shows 08/25/2035; the form does not provide additional performance conditions, cash payments, or explicit grant fair-value figures. For investors, this filing is a standard disclosure of insider compensation rather than an operational or financial performance signal.
TL;DR: Standard governance disclosure: director received an equity-based award with time-based vesting tied to an S-8 filing.
The Form 4 is consistent with customary director compensation through equity incentives. It specifies direct beneficial ownership post-grant and a clear vesting formula tied to the S-8 registration date and a 48-month monthly vesting schedule measured from April 25, 2025. The filing does not indicate acceleration clauses, change-in-control terms, or departures from typical equity award governance. The document is informational for compliance with Section 16 reporting obligations and does not by itself indicate any governance irregularity.
BridgeBio Oncology Therapeutics, Inc. il direttore Jake Bauer ha dichiarato l'acquisizione di un'opzione su azioni in data 26/08/2025. Il Modulo 4 segnala una concessione (codice transazione A) di una Stock Option (Diritto di Acquisto) relativa a 138.193 azioni ordinarie sottostanti, con prezzo di esercizio pari a $9,59. Il documento riporta la detenzione di 138.193 titoli derivati dopo l'operazione e indica che l'opzione 猫 di propriet脿 diretta. Nella tabella la colonna esercitabile/scadenza riporta la data 25/08/2035. La nota sul vesting specifica che la maturazione 猫 subordinata al deposito di un S-8 e poi avviene mensilmente su un periodo di 48 mesi a partire dalla data di inizio del vesting del 25 aprile 2025. Il Modulo 4 猫 stato firmato da un procuratore il 28/08/2025.
BridgeBio Oncology Therapeutics, Inc. el director Jake Bauer inform贸 la adquisici贸n de una opci贸n sobre acciones el 26/08/2025. El Formulario 4 revela una concesi贸n (c贸digo de transacci贸n A) de una Stock Option (Derecho de Compra) sobre 138.193 acciones ordinarias subyacentes, con un precio de ejercicio de $9,59. El formulario indica la tenencia de 138.193 valores derivados tras la operaci贸n y clasifica la opci贸n como propiedad directa. La tabla muestra la fecha 25/08/2035 en la columna de ejercitable/vencimiento. La presentaci贸n incluye una descripci贸n del vesting: la adquisici贸n de derechos est谩 sujeta a la presentaci贸n del formulario S-8 y, a continuaci贸n, se produce un vesting mensual durante 48 meses contado desde la fecha de inicio de vesting del 25 de abril de 2025. El Formulario 4 fue firmado por un apoderado el 28/08/2025.
BridgeBio Oncology Therapeutics, Inc.鞚� 鞚挫偓 Jake Bauer電� 2025-08-26鞐� 鞀ろ啞鞓奠厴鞚� 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. Form 4電� 瓯半灅旖旊摐 A搿� 響滉赴霅� 鞀ろ哑鞓奠厴(毵れ垬甓�) 攵�鞐ゼ 瓿店皽頃橂┌, 旮办磮 氤错喌欤� 138,193欤检棎 雽�頃� 甓岆Μ鞚搓碃 頄夓偓臧�瓴╈潃 $9.59鞛呺媹雼�. 頃措嫻 靹滊鞐愲姅 瓯半灅 頉� 韺岇儩歃濌秾 138,193欤茧ゼ 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 旮办灛霅橃柎 鞛堨溂氅�, 鞓奠厴鞚� 歆侅为 靻岇湢搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 響滌潣 頄夓偓/毵岆 旃胳棎電� 2035-08-25霛茧姅 雮犾臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氩犾姢韺� 靹る獏鞐愲姅 氩犾姢韺� 臧滌嫓臧� S-8 鞝滌稖鞐� 鞐半彊霅橂┌, 攴� 頉� 2025雲� 4鞗� 25鞚�鞚� 氩犾姢韺� 臧滌嫓鞚茧攵�韯� 48臧滌洈鞐� 瓯胳硱 毵れ洈 氩犾姢韺呺悳雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Form 4電� 雽�毽澑鞚� 2025-08-28鞐� 靹滊獏頄堨姷雼堧嫟.
BridgeBio Oncology Therapeutics, Inc. : le directeur Jake Bauer a d茅clar茅 l'acquisition d'une option d'achat d'actions le 26/08/2025. Le formulaire 4 d茅voile une attribution (code de transaction A) d'une Stock Option (droit d'achat) couvrant 138鈥�193 actions ordinaires sous-jacentes, avec un prix d'exercice de 9,59 $. Le formulaire indique la d茅tention de 138鈥�193 titres d茅riv茅s apr猫s la transaction et pr茅cise que l'option est en propri茅t茅 directe. Le tableau affiche la date 25/08/2035 dans la colonne exer莽able/expiration. La description du vesting pr茅cise que la mont茅e de droits d茅pend du d茅p么t d'un S-8, puis se r茅alise mensuellement sur 48 mois 脿 compter de la date de commencement du vesting du 25 avril 2025. Le formulaire 4 a 茅t茅 sign茅 par un mandataire le 28/08/2025.
BridgeBio Oncology Therapeutics, Inc.-Direktor Jake Bauer meldete den Erwerb einer Aktienoption am 26.08.2025. Das Formular 4 gibt einen Zuschuss (Transaktionscode A) einer Stock Option (Kaufrecht) 眉产别谤 138.193 zugrunde liegende Stammaktien mit einem Aus眉bungspreis von $9,59 an. Das Formular weist 138.193 derivativen Wertpapiere nach der Transaktion aus und nennt die Option als direktes Eigentum. In der Tabelle steht in der Spalte Aus眉bbar/Verfall das Datum 25.08.2035. Zur Vesting-Regelung hei脽t es, dass das Vesting an die Einreichung eines S-8 gebunden ist und anschlie脽end 眉产别谤 einen Zeitraum von 48 Monaten monatlich erfolgt, gemessen ab dem Vesting-Beginn am 25. April 2025. Das Formular 4 wurde am 28.08.2025 von einem Bevollm盲chtigten unterschrieben.
FAQ
What did Jake Bauer (director) report on Form 4 for BBOT?
How many shares does the reported option cover and who owns them?
What are the vesting terms for the option reported on Form 4?
What is the exercise price and transaction date disclosed?
Who signed the Form 4 and when was it signed?
